Senores Pharmaceuticals Ltd IPO

Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.

Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.

Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.

Presence in the Emerging Markets with a product portfolio, including specialty or complex products.

R&D capabilities driving our differentiated portfolio of products.

Professional management teams for our diverse business verticals.

The company business is dependent on the sale of its products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for its products or the company inability to maintain and increase the number of its arrangements for the marketing and distribution of the company products could adversely affect its business, results of operations, financial conditions and cash flows.

The company business is dependent on the sale of its products and continued growth of the Regulated Markets. Decrease in market growth for its product or failures to respond to change in market conditions could adversely affect its business, results of operations, financial conditions and cash flows.

Failures to comply with the quality standards and technical specifications prescribed by its customers may lead to loss of business from such customers and could negatively impact its business, results of operations and financial condition, including cancellation of existing and future orders which may expose it to warranty claims.

The company derives a part of its revenue from few customers. If one or more of such customers choose not to source their requirements from it or to terminate the company contracts or purchase orders, its business, cash flows, financial condition and results of operations may be adversely affected.

The company has had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on its business and operations.

The pharmaceutical market is subject to regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose it to litigation or other liabilities, which could adversely affect its reputation, business, financial condition and results of operations. There have been instances in the past where the company drugs failed to meet standards prescribed under applicable law and action was taken against it by regulatory authorities.

The company derives a major portion of its revenue from its operations in the United States. A reduction in demand for the company products in these regions could adversely affect its business, results of operations, financial conditions and cash flows.

Any manufacturing or quality control problems may damage its reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, results of operations and financial condition.

Some of its Directors and Promoters may have interest in entities, which are in businesses similar to its and this may result in conflict of interest with it. Further, certain of its Promoter Group, Subsidiaries and Group Companies are in the same line of business as it, which may result in a conflict of interest.

The erstwhile statutory auditors of the Company have issued a qualified opinion in connection with their audit report for Fiscal 2022.